Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19
- PMID: 33623808
- PMCID: PMC7888564
- DOI: 10.1093/ofid/ofab050
Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19
Abstract
We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvoxamine and 12.5% (6 of 48) with observation alone. At 14 days, residual symptoms persisted in 0% (0 of 65) with fluvoxamine and 60% (29 of 48) with observation.
Keywords: COVID-19; SARS-COV-2; cohort; coronavirus; fluvoxamine.
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Similar articles
-
Early Fluvoxamine Reduces the Risk for Clinical Deterioration in Symptomatic Outpatients with COVID-19: A Real-World, Retrospective, before-after Analysis.Microorganisms. 2023 Aug 12;11(8):2073. doi: 10.3390/microorganisms11082073. Microorganisms. 2023. PMID: 37630633 Free PMC article.
-
Impact of fluvoxamine on outpatient treatment of COVID-19 in Honduras in a prospective observational real-world study.Front Pharmacol. 2022 Nov 30;13:1054644. doi: 10.3389/fphar.2022.1054644. eCollection 2022. Front Pharmacol. 2022. PMID: 36532727 Free PMC article.
-
Characteristics and Outcomes of 241 Births to Women With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection at Five New York City Medical Centers.Obstet Gynecol. 2020 Aug;136(2):273-282. doi: 10.1097/AOG.0000000000004025. Obstet Gynecol. 2020. PMID: 32555034
-
The Coronavirus Pandemic: What Does the Evidence Show?J Nepal Health Res Counc. 2020 Apr 19;18(1):1-9. doi: 10.33314/jnhrc.v18i1.2596. J Nepal Health Res Counc. 2020. PMID: 32335585 Review.
-
Pathogenesis-directed therapy of 2019 novel coronavirus disease.J Med Virol. 2021 Mar;93(3):1320-1342. doi: 10.1002/jmv.26610. Epub 2020 Nov 10. J Med Virol. 2021. PMID: 33073355 Review.
Cited by
-
Antidepressant use and risk of intubation or death in hospitalized patients with COVID-19: A retrospective cohort study of clinical effectiveness.Front Psychiatry. 2022 Sep 15;13:951065. doi: 10.3389/fpsyt.2022.951065. eCollection 2022. Front Psychiatry. 2022. PMID: 36186877 Free PMC article.
-
Antidepressant Drugs and COVID-19: A Review of Basic and Clinical Evidence.J Clin Med. 2022 Jul 12;11(14):4038. doi: 10.3390/jcm11144038. J Clin Med. 2022. PMID: 35887802 Free PMC article. Review.
-
The acid sphingomyelinase/ceramide system in COVID-19.Mol Psychiatry. 2022 Jan;27(1):307-314. doi: 10.1038/s41380-021-01309-5. Epub 2021 Oct 4. Mol Psychiatry. 2022. PMID: 34608263 Free PMC article. Review.
-
Sialylated Glycan Bindings from SARS-CoV-2 Spike Protein to Blood and Endothelial Cells Govern the Severe Morbidities of COVID-19.Int J Mol Sci. 2023 Dec 1;24(23):17039. doi: 10.3390/ijms242317039. Int J Mol Sci. 2023. PMID: 38069362 Free PMC article. Review.
-
Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis.Ann Med. 2022 Dec;54(1):516-523. doi: 10.1080/07853890.2022.2034936. Ann Med. 2022. PMID: 35118917 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous